Pemvidutide
Phase 3 liver trial under way; it reports in 2029.
A weekly injection aimed at the liver first and weight second. It is also being tested in alcohol use disorder. A made by Altimmune, also called ALT-801.
What the evidence shows
Side effects and risks
Who should avoid it: Anyone outside a clinical trial.
How it works
- Where it acts
- GLP-1 and glucagon receptors, in equal balance.
- What it changes
- Aimed at liver fat first: glucagon drives fat burning in the liver while GLP-1 lowers appetite.
- What people notice
- In trials, less liver fat and inflammation, with weight loss as a second effect. Stomach side effects occur.
How it has been given in trials
Weekly injection under the skin. There is no approved dose.
Getting it in the United States
The legal route for Pemvidutide
Not approved. The only lawful way to get it is to join a clinical trial.
Clinical trial enrollment only
Investigational and not approved anywhere. The lawful route is a trial place, mainly the global phase 3 MASH study that started in mid 2026. Participants may be assigned placebo, and results are not due until 2029.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextWhat public figures say, videos and articles and when options run out
What experts and influencers say
Paraphrased from the linked sources.
Presented 24-week IMPACT data at the 2025 liver meeting. Said MASH resolution was strong, the fibrosis miss on standard biopsy reading reflected a high placebo rate, and longer studies are needed.
Source: HCPLive, Nov 2025
Mazen NoureddinWebsiteRecommends
Money: Reports disclosures with Altimmune and several other liver-drug companies
Photo source: houstonmethodist.org
Kept a neutral rating after the 24-week readout. Judged the results underwhelming because fibrosis missed significance, doubted the 48-week fibrosis goal without a biopsy, and saw unclear differentiation in a crowded MASH field.
Source: Benzinga, Jun 2025
Andy HsiehWebsiteWarns against
Photo source: qb3.berkeley.edu
Reported that 48-week data showed deeper weight loss at the high dose and better noninvasive fibrosis markers, but no biopsies were taken and investors still looked skeptical.
Source: Fierce Biotech, Dec 2025
Fierce BiotechSourceMixed view
Kept a buy rating after the 24-week readout. Argued the data justify a phase 3 trial and that the share price fall was overdone.
Source: Benzinga, Jun 2025
Patrick TrucchioWebsiteRecommends
Photo source: biotechtv.com
After the alcohol use disorder trial readout, said the company was encouraged and argued the glucagon component acts on the liver in a way GLP-1 alone does not.
Source: BioSpace, Jul 2026
Christophe Arbet-EngelsSourceRecommends
Money: Executive of the developer
In second-quarter 2026 results, pointed to the phase 3 MASH trial start and the alcohol trial data as milestones, and described both conditions as large unmet needs with sales potential.
Jerry DursoSourceRecommends
Money: Executive of the developer
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Altimmune eyes phase 3 MASH trial as weight loss deepens
Nick Paul Taylor, reporter
Reports 48-week phase 2 liver-disease data for pemvidutide, with continued weight loss and better fibrosis markers at the high dose, while investors stay wary.
Best single update on the liver-disease program.
Altimmune's next-gen GLP-1 curbs heavy drinking in 'unequivocal' ph. 2 alcohol use disorder win
Darren Incorvaia, reporter
Describes a phase 2 trial in which pemvidutide, a dual GLP-1 and glucagon drug, reduced heavy drinking days in people with alcohol use disorder.
Newest result, showing a use beyond weight loss.
Analyst still sees potential in Altimmune obesity drug after shares plunged on dropout data
James Waldron, reporter
Early obesity data showed a high dropout rate, about half from stomach side effects, which hit the stock; analysts said weight loss still looked competitive.
Older but frank look at the tolerability problem.
When options run out
Uses people turn to when standard treatment has failed.
Alcohol use disorder with overweight
- Who
- People with alcohol use disorder, who have few approved drug options and often also have fatty liver and obesity.
- Evidence
- One phase 2 trial of 100 people over 24 weeks. Heavy drinking days fell more than on placebo. Company-reported topline data, not yet peer reviewed.
- Route
- Phase 2 RECLAIM trial completed. Company plans an end-of-phase-2 meeting with the FDA. No expanded access reported.
Source: BioSpace, Jul 2026
Alcohol-associated liver disease
- Who
- People with liver damage from heavy drinking, a group with no approved drug treatment.
- Evidence
- No results yet. A 48-week phase 2 trial of about 120 people finished enrolling in 2026. Topline data expected in the second half of 2027.
- Route
- Phase 2 RESTORE trial, enrollment closed
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
What is pemvidutide used for?
It is aimed at fatty liver disease (MASH) first and weight second. It is also being tested in alcohol use disorder.
Does pemvidutide work for fatty liver disease?
In a phase 2b trial, MASH cleared in roughly half to six in ten people at 24 weeks, against about one in five on placebo. Scarring did not clearly improve in that time.
Does pemvidutide help with alcohol use disorder?
The company reported a positive result from a 100-person phase 2 trial in July 2026. The trial is small and unpublished.
Is pemvidutide approved?
No. A phase 3 liver trial has started and reports in 2029, and the drug has FDA Breakthrough designation.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem